BRIEF-CTI Biopharma says completed enrollment in phase 3 PIX306 trial of Pixuvri
August 02, 2017 at 01:42 AM EDT
* Announced completion of enrollment in phase 3 PIX306 trial of Pixuvri to treat aggressive B-cell non-Hodgkin lymphoma Source text for Eikon: Further company coverage: (Reporting by Milan Newsroom)
